1 terminated, 1 withdrawn. 2 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Withdrawn 1 |
Follow PSA Level Greater Than or Equal to Two: new trials by email Literature Review of PSA Level Greater Than or Equal to Two trials Research Report on PSA Level Greater Than or Equal to Two
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer Decitabine, Enzalutamide - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2021-04-15 | 2022-10-05 | |
| Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency Carboplatin, Docetaxel, Laboratory Biomarker Analysis - ATM Gene Mutation, BRCA1 Gene Mutation | Phase 2 | Terminated | University of Washington | 18 | 2018-08-24 | 2026-08-26 |
Genital Diseases (1) · Genital Diseases, Male (1) · Genital Neoplasms, Male (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Site (1) · Prostatic Diseases (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1)
Carboplatin (1) · Decitabine (1) · Docetaxel (1) · Injections (1) · enzalutamide (1) · rucaparib (1)
Roswell Park Cancer Institute (1) · University of Washington (1)
United States (2)
Gurkamal Chatta (1) · Heather H. Cheng (1)